Abstract
Invasive fungal infections are a serious threat to public health, particularly to people with compromised or suppressed immunity. Although the current antifungal therapies have been significantly improved, the outcome is still far from satisfactory, partly due to the limited number of classes of clinically available antifungals, the development of resistance to current antifungals, and the challenges of proper and early diagnosis. Recent advances in the development of new antifungals, although still in the investigational stages, offer some new hope of improving the future of antifungal therapy. Here, we review literature regarding the antifungal activities of several FDA-approved drugs, which were originally intended for treating other conditions, as well as newly discovered natural/artificial compounds. We focus on their mechanisms of action, limitations, and potential in treating fungal infections. The diverse mechanisms of action of these compounds summarized here can provide new directions for future endeavors on antifungal drug development.
Keywords: Polymyxin, tamoxifen, amiodarone, sertraline, occidiofungin, saponins, retigeric acid B, arylamidine derivative, drug synergy, compromised or suppressed immunity, antifungals, antifungal therapy, amphotericin B, azole therapy
Current Pharmaceutical Biotechnology
Title: Recent Progress on Antifungal Drug Development
Volume: 12 Issue: 8
Author(s): Bing Zhai and Xiaorong Lin
Affiliation:
Keywords: Polymyxin, tamoxifen, amiodarone, sertraline, occidiofungin, saponins, retigeric acid B, arylamidine derivative, drug synergy, compromised or suppressed immunity, antifungals, antifungal therapy, amphotericin B, azole therapy
Abstract: Invasive fungal infections are a serious threat to public health, particularly to people with compromised or suppressed immunity. Although the current antifungal therapies have been significantly improved, the outcome is still far from satisfactory, partly due to the limited number of classes of clinically available antifungals, the development of resistance to current antifungals, and the challenges of proper and early diagnosis. Recent advances in the development of new antifungals, although still in the investigational stages, offer some new hope of improving the future of antifungal therapy. Here, we review literature regarding the antifungal activities of several FDA-approved drugs, which were originally intended for treating other conditions, as well as newly discovered natural/artificial compounds. We focus on their mechanisms of action, limitations, and potential in treating fungal infections. The diverse mechanisms of action of these compounds summarized here can provide new directions for future endeavors on antifungal drug development.
Export Options
About this article
Cite this article as:
Zhai Bing and Lin Xiaorong, Recent Progress on Antifungal Drug Development, Current Pharmaceutical Biotechnology 2011; 12 (8) . https://dx.doi.org/10.2174/138920111796117292
DOI https://dx.doi.org/10.2174/138920111796117292 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Geniposide Attenuates Mitochondrial Dysfunction and Memory Deficits in APP/PS1 Transgenic Mice
Current Alzheimer Research Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases
Current Drug Discovery Technologies Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Advances in Helper-Dependent Adenoviral Vector Research
Current Gene Therapy Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types
Current Cancer Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry